Synthetic Δ-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia

Journal of Clinical Psychopharmacology

Volumn 29, Issue 3, 2009, Pages 255-258

  Schwarcz, Glenn ^a,b,c   Karajgi, Basawaraj ^a   McCarthy, Richard ^d,e  

^a Rockland Psychiatric Center   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d State of New York Office of Mental Health ^*  (United States)

^e Pilgrim Psychiatric Center   (United States)

Author keywords

Cannabinoid hypothesis of schizophrenia; Endocannabinoid stimulation

Indexed keywords

CLOZAPINE; DRONABINOL; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; FUNCTIONAL STATUS; HUMAN; MALE; MENTAL DETERIORATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TETRAHYDROCANNABINOL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649265233     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181a6bc3b     Document Type: Article

References (26)

1. Van Sickle MD, Oland LD, Mackie K, et al. Delta-9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol. 2003;48:G566-G576.
2. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs. 1998;30:187-196.
3. Marinol. Available at: http://www.fda.gov/medWatch/safety/2006/ Jun-Pls/Marinol-Pl.pdf. Accessed November 19, 2007.
4. Guy W. CGI Clinical global impressions: ECDEU Assessment Manual Rev ed. Rockville, MD: Department of Health, Education, and Welfare; 1976:218-222.
5. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
6. Mathers DC, Ghodse AH. Cannabis and psychotic illness. Br J Psychiatry. 1992;161:648-653.
7. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57:594-608.
8. Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry. 1974;30:24-27.
9. Favrat B, Menetrey A, Augsburger M, et al. Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry. 2005;5:17. Available at: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=1079888. Accessed November 7, 2008.
10. Muller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother. 2008;8:1037-1048.
11. Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004;99:425-430.
12. Henquet C, Di Forte M, Morrison P, et al. Gene-environment interplay between cannabis and psychosis. Schizophrenia Bull. 2008;34:1111-1121.
13. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia. Pharmacol Biochem Behav. 1997;56:803-807.
14. Ujike H, Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci. 2004;96:376-381.
15. Zachariou M, Dissanayake DWN, Markus RO, et al. The role of cannabinoids in the neurobiology of sensory gating: a firing rate model study. Neurocomputing. 2007;70:1902-1906.
16. Ballmaier M, Bortolato M, Rizzetti C, et al. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology. 2007;32:2098-2107.
17. Johannesen JK, Bodkins M, O'Donnell BF, et al. Perceptual anomalies in schizophrenia co-occur with selective impairments in the gamma frequency component of midlatency auditory ERPs. J Abnormal Psychol. 2008;117:106-118.
18. Leavitt VM, Molholm S, Ritter W, et al. Auditory processing in schizophrenia during the middle latency period (10-50 ms). J Psychiatry Neurosci. 2007;32:339-353.
19. Meltzer H, Arvanitis L, Bauer D, et al. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161:975-984.
20. Bambico FR, Katz N, Debonnel G, et al. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci. 2007;27:13369-13370.
21. Walther S, Mahlberg R, Eichmann U, et al. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006;185:524-528.
22. Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9:164-173.
23. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet. 2007;370:1706-1713.
24. Kedzior KK, Badcock JC, Martin-Iverson MT. Validity and consistency of self-reports regarding substance abuse in general research volunteers, including regular cannabis users and schizophrenic patients. Subst Use Misuse. 2006;41:743-750.
25. Costain FC. The effects of cannabis abuse on the symptoms of schizophrenia: patient perspectives. Int J Ment Health Nurs. 2008;17:227-235.
26. Kales HC, Valenstein M, Kim HN, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164:1568-1576.